Blockchain Registration Transaction Record

Telomir Pharmaceuticals Consolidates Global Rights to Telomir-Zn

Telomir Pharmaceuticals closes acquisition of TELI, securing global rights to Telomir-Zn. With $1M funding and IND submission for triple-negative breast cancer, the company advances toward Phase 1/2 trials.

This acquisition matters because it consolidates global rights to Telomir-Zn, eliminating fragmentation and positioning the company for a streamlined clinical development path. For investors, it signals a stronger commitment to advancing a promising therapy targeting triple-negative breast cancer, a disease with limited treatment options. The additional milestone-based funding provides financial runway for upcoming trials, making this a key event for stakeholders in the biotech space.